Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)

Applied Radiation and Isotopes

Volumn 95, Issue , 2015, Pages 135-142

  Lam, Karen ^a   Scollard, Deborah A ^a,b   Chan, Conrad ^a   Levine, Mark N ^c   Reilly, Raymond M ^a,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Good manufacturing practices (GMP); HER2; Indium 111; Pertuzumab; Radiopharmaceutical kit

Indexed keywords

BREAST CANCER; GOOD MANUFACTURING PRACTICES; HER2; HERCEPTIN; PERTUZUMAB; RADIOPHARMACEUTICAL KIT; TRASTUZUMAB;

2 (4 ISOTHIOCYANATOBENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID; 2 (4 ISOTHIOCYANATOBENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID PERTUZUMAB IN 111; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG STABILITY; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; TISSUE DISTRIBUTION;

EID: 84909619133     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2014.10.011     Document Type: Article

References (26)

1. Adams C.W., Allison DE., Flagella K., Presta L., Clarke J., Dybdal N., McKeever K., Sliwkowski M.X. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother. 2006, 55:717-727.
2. Anonymous Prostascint Kit (capromab pendetide). Kit for the preparation of indium In111 capromab pendetide 2012.
3. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur. J. Cancer 2001, 37:S18-S24.
4. Brechbiel M.W., Gansow O.A., Atcher R.W., Schlom J., Esteban J., Simpson D.E., Colcher D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg. Chem. 1986, 25:2772-2781.
5. Chari R.V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 2008, 41:98-107.
6. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2010, 87:586-592.
7. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.A., Pedrini J.L., Poirier B., Morandi P., Semiglazov V., Srimuninnimit V., Bianchi G., Szado T., Ratnayake J., Ross G., Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012, 13:25-32.
8. Lam K., Chan C., Done S.J., Levine M.N., Reilly R.M., Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicology studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab, Nucl. Med. Biol, in press. http://dx.doi.org/10.1016/j.nucmedbio.2014.09.011.
9. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., Chan S., Grimes D., Anton A., Lluch A., Kennedy J., O'Byrne K., Conte P., Green M., Ward C., Mayne K., Extra J.M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 2005, 23:4265-4274.
10. 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J. Nucl. Med. 2009, 50:1340-1348.
11. 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur. J. Nucl. Med. Mol. Imag. 2009, 36:81-93.
12. Morris M.J., Divgi C.R., Pandit-Taskar N., Batraki M., Warren N., Nacca A., Smith-Jones P., Schwartz L., Kelly W.K., Slovin S., Solit D., Halpern J., Delacruz A., Curley T., Finn R., O'Donoghue J, Livingston A., Larson P., Scher, H.I.S. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin. Cancer Res. 2005, 11:7454-7461.
13. 64Cu-DOTA-trastuzumab PET. J. Nucl. Med. 2014, 55:23-29.
14. Nahta R., Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232:123-138.
15. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 2006, 3:269-280.
16. Perik P.J., Lub-de Hooge M.N., Gietema J.A., van der Graaf W.T.A., de Korte M.A., Jonkman S., Kosterink J.G.W., van Veldhuisen D.J., Sleijfer D.T., Jager P.L., de Vries E.G.E. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 2006, 24:2276-2282.
17. 177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur. J. Nucl. Med. Mol. Imag. 2005, 32:1457-1462.
18. Reilly R. The immunoreactivity of radiolabeled antibodies: its impact on tumor targeting and strategies for preservation. Cancer Biother. Radiopharm. 2004, 19:669-672.
19. 111In for radiotherapeutic applications. J. Nucl. Med. 2004, 45:701-708.
20. 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER-2 positive breast cancer. Nucl. Med. Biol. 2011, 38:129-136.
21. Scott A.M., Tebbutt N., Lee F.T., Cavicchiolo T., Liu Z., Gill S., Poon A.M., Hopkins W., Smyth F.E., Murone C., MacGregor D., Papenfuss A.T., Chappell B., Saunder T.H., Brechbiel M.W., Davis I.D., Murphy R., Chong G., Hoffman E.W., Old L.J. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin. Cancer Res. 2007, 13:3286-3292.
22. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M.A., Riva A., Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365:1273-1283.
23. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
24. Swain S.M., Kim S.B., Cortes J., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.M., Schneeweiss A., Knott A., Clark E., Ross G., Benyunes M.C., Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013, 14:461-471.
25. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J. Nucl. Med. 2013, 54:1869-1875.
26. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., Spears P.A., Vance G.H., Viale G., Hayes D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013, 31:3997-4013.